AML‐Targeted Metal‐Polyphenol Nanoplatform Induces Ferroptosis‐ICD Cascade for Antitumor Immunity Boosting
Advanced Science · 2026-05 · 13 (27)
DOI: 10.1002/advs.202520544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 03.03.2026. Verfasst von Shangqin Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu…. Hauptthemen laut MEDLINE: Ferroptosis, Leukemia, Myeloid, Acute, Polyphenols, Immunogenic Cell Death. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sichuan Science and Technology Program, Chengdu Science and Technology Project.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) remains a therapeutic challenge due to its low immunogenicity and immunosuppressive tumor microenvironment (iTME). We developed a ferritin‐based nanoplatform (Fe‐SH@Fn) co‐delivering shikonin (SH) and Fe 3+ to synergistically induce ferroptosis and activate immunogenic cell death (ICD). Ferritin, a ligand for CD71, which is overexpressed on AML cells, enables tumor targeting and encapsulates Fe‐SH formed by coordination between SH and Fe 3+ . In AML cells, high intracellular glutathione triggers Fe‐SH@Fn disassembly: Fe 3+ reduces to Fe 2+ to drive Fenton reaction‐mediated ferroptosis, while SH induces ICD. This dual effect boosts the release of damage‐associated molecular patterns, remodeling the microenvironment by promoting dendritic cell maturation, enhancing CD8 + T cell infiltration, and reducing regulatory T cells. In vivo, Fe‐SH@Fn achieved 81.25% tumor growth inhibition in subcutaneous AML model and extended median survival by 2.8‐fold in orthotopic AML model without systemic toxicity. This work presents a translatable strategy that overcomes AML immunosuppression through targeted drug delivery and synergistic ferroptosis‐ICD activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- School of Pharmacy, Southwest Medical University, Luzhou, China.
- Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- College of Pharmacy, Chengdu University, Chengdu, China.
ORCID-Profile: Lulu Cai
Förderung
- National Natural Science Foundation of China
- Sichuan Science and Technology Program
- Chengdu Science and Technology Project
- Sichuan Provincial Medical Youth Innovation Research Project
Zitieren
APA
Yang, S., Wang, J., Tu, K., Huang, X., Lv, L., Peng, M., Xu, Q., Liu, H., Sun, Q., & Cai, L. (2026). AML‐Targeted Metal‐Polyphenol Nanoplatform Induces Ferroptosis‐ICD Cascade for Antitumor Immunity Boosting. Advanced Science, 13(27). https://doi.org/10.1002/advs.202520544
Vancouver
Yang S, Wang J, Tu K, Huang X, Lv L, Peng M, et al. AML‐Targeted Metal‐Polyphenol Nanoplatform Induces Ferroptosis‐ICD Cascade for Antitumor Immunity Boosting. Advanced Science. 2026;13(27). doi:10.1002/advs.202520544
BibTeX
@article{Yang2026,
author = {Yang, Shangqin and Wang, Jingxuan and Tu, Kerong and Huang, Xiaobing and Lv, Liangliang and Peng, Mingjie and Xu, Qiqi and Liu, Hongmei and Sun, Qiang and Cai, Lulu},
title = {AML‐Targeted Metal‐Polyphenol Nanoplatform Induces Ferroptosis‐ICD Cascade for Antitumor Immunity Boosting},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {27},
doi = {10.1002/advs.202520544}
}
EUVIMED